| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PRQR Stock Overview
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.25 |
| 52 Week High | US$9.46 |
| 52 Week Low | US$4.05 |
| Beta | 0.39 |
| 1 Month Change | -18.30% |
| 3 Month Change | -18.41% |
| 1 Year Change | 47.06% |
| 3 Year Change | -58.80% |
| 5 Year Change | 48.81% |
| Change since IPO | -57.57% |
Recent News & Updates
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Investment Case On ProQR Therapeutics Gets More Enticing
Today, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year. The company recently inked a significant collaboration deal with drug giant Eli Lilly which makes its investment case more enticing. We update the investment thesis on ProQR Therapeutics to account for recent events in the paragraphs below.
Shareholder Returns
| PRQR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | -6.2% | -4.6% |
| 1Y | 47.1% | -19.8% | 7.7% |
Return vs Industry: PRQR exceeded the US Biotechs industry which returned -18.4% over the past year.
Return vs Market: PRQR exceeded the US Market which returned 10.2% over the past year.
Price Volatility
| PRQR volatility | |
|---|---|
| PRQR Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: PRQR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: PRQR's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 150 | Daniel de Boer | https://www.proqr.com |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber’s congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
ProQR Therapeutics Fundamentals Summary
| PRQR fundamental statistics | |
|---|---|
| Market Cap | €391.84m |
| Earnings (TTM) | -€56.62m |
| Revenue (TTM) | €2.19m |
178.6x
P/S Ratio-6.9x
P/E RatioIs PRQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR income statement (TTM) | |
|---|---|
| Revenue | €2.19m |
| Cost of Revenue | €0 |
| Gross Profit | €2.19m |
| Expenses | €58.81m |
| Earnings | -€56.62m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,580.54% |
| Debt/Equity Ratio | 15.1% |
How did PRQR perform over the long term?
See historical performance and comparisonValuation
Is ProQR Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRQR ($6.25) is trading below our estimate of fair value ($92.52)
Significantly Below Fair Value: PRQR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRQR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PRQR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRQR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRQR is overvalued based on its PB Ratio (3x) compared to the US Biotechs industry average (2.1x).
Future Growth
How is ProQR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
35.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRQR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRQR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRQR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRQR's revenue (59.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: PRQR's revenue (59.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRQR is forecast to be unprofitable in 3 years.
Past Performance
How has ProQR Therapeutics performed over the past 5 years?
-7.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRQR is currently unprofitable.
Growing Profit Margin: PRQR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRQR is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: PRQR has a negative Return on Equity (-44.26%), as it is currently unprofitable.
Financial Health
How is ProQR Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PRQR's short term assets (€177.1M) exceed its short term liabilities (€34.7M).
Long Term Liabilities: PRQR's short term assets (€177.1M) exceed its long term liabilities (€32.6M).
Debt to Equity History and Analysis
Debt Level: PRQR has more cash than its total debt.
Reducing Debt: PRQR's debt to equity ratio has increased from 7.9% to 15.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRQR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PRQR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is ProQR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRQR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRQR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRQR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRQR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRQR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Daniel de Boer (38 yo)
9.92yrs
Tenure
€2,624,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He founded ProQR Therapeutics N.V. in February 2012. Mr. de...
CEO Compensation Analysis
Compensation vs Market: Daniel's total compensation ($USD2.98M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: PRQR's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: PRQR's board of directors are considered experienced (4.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.9%.
Top Shareholders
Company Information
ProQR Therapeutics N.V.'s employee growth, exchange listings and data sources
Key Information
- Name: ProQR Therapeutics N.V.
- Ticker: PRQR
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$444.716m
- Shares outstanding: 71.15m
- Website: https://www.proqr.com
Number of Employees
Location
- ProQR Therapeutics N.V.
- Zernikedreef 9
- Leiden
- Zuid-Holland
- 2333 Ck
- Netherlands
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/19 23:48 |
| End of Day Share Price | 2022/01/19 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.